Excellence in research
On 20 March 2019, Université Paris Cité has been founded in conjunction with the Institut de Physique du Globe de Paris, a third establishment of higher education that continues to maintain its legal independence. The two founding universities, the University of Paris Diderot and the University of Paris Descartes were awarded an HRS4R label respectively in July 2017 and in November 2017.

The European Human Resources Strategy for Researchers, also known as HRS4R, aims to improve the practices of research organizations and institutions with regard to the recruitment and working conditions of researchers within the field of academic research.
It is the focus of an HR Excellence in Research label awarded by the European Commission to institutions engaged in this process.
Within the framework of the European Research Area (ERA), the European Union has endeavored to promote the attractiveness of the research profession as well as to foster mobility and build true career prospects.
To achieve these objectives, in 2005, the European Commission created the European Research Charter along with the Code of Conduct for the Recruitment of Researchers, which define the roles, responsibilities and rights of researchers and their employers. The Charter and Code (C&C) are intended to ensure attractive research careers and to improve the recruitment and working conditions of researchers in Europe.
These objectives fully align with Université Paris Cité policy of supporting excellence in research. These initiatives aim to strengthen the site’s attractiveness and international influence and ensure its successful integration into the European Research Area.
On 20 March 2019, Université Paris Cité has been founded in conjunction with the Institut de Physique du Globe de Paris, a third establishment of higher education that continues to maintain its legal independence. The two founding universities, the University of Paris Diderot and the University of Paris Descartes were awarded an HRS4R label respectively in July 2017 and in November 2017.
The Institut de Physique du Globe de Paris (IPGP) is currently a candidate for the HRS4R label.
In the autumn of 2019, the two founding universities informed the European Commission of the creation of Université Paris Cité and requested authorization to submit a new application for the HRS4R label in the name of the new establishment. They were given this authorization. Since then, the two universities have each forwarded their internal self evaluations—two years after obtaining their respective labels as planned—and have pursued the preparatory work for a joint action plan, merging the action plans originally set forth by the two establishments.
Adopting a voluntary, flexible but determined quality approach based on the model proposed by the European Union as part of the European Human Resources Strategy (HRS4R) provides a useful and effective framework for ongoing actions initiated in this regard.
Contact
info.hrs4r@u-paris.fr
Focus on
The European Research Charter
Read more
![[CLOVES syndrome] : The U.S. FDA approves Alpelisib based on a French study](https://u-paris.fr/wp-content/uploads/2022/04/julia-koblitz-4AsRcVTJYTw-unsplash-1080x675.jpg)
[CLOVES syndrome] : The U.S. FDA approves Alpelisib based on a French study
AP-HP, Inserm and Université Paris Cité extend their congratulations to Professor Guillaume Canaud’s teams at Necker-Enfants Malades Hospital (AP-HP), Necker-Enfants Malades Institute (INEM), Inserm, Institut Imagine and Université Paris Cité for their work on alpelisib (BYL719), approved by the US Food and Drug Administration (FDA).

Université Paris Cité awarded the “Science with and for Society” Label
On April 13th, the French Ministry of Higher Education, Research and Innovation announced the 12 new winners of the "Science with and for Society" label. (Science avec et pour la société). Université Paris Cité has joined 17 other institutions who have been granted...
![[SARS-CoV-2] Neutralization of BA.1 and BA.2 by therapeutic monoclonal antibodies](https://u-paris.fr/wp-content/uploads/2022/04/cellules-infectées-par-omicron-1080x675.jpg)
[SARS-CoV-2] Neutralization of BA.1 and BA.2 by therapeutic monoclonal antibodies
The SARS-CoV-2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. Although Omicron is responsible for less severe forms in the general population, immunocompromised people are still at higher risk of developing severe forms of...

Crowd4SDG featured at the Geneva Trialogue 2022
In the context of the Geneva Trialogue, the European research project Crowd4SDG held a hybrid workshop on March 17th called "Closing the gap between institutions and citizen science generated data and solutions". © Geneva Trialogue During the Geneva Trialogue...